Patienter, som anvender andre lægemidler, der hæmmer renin- angiotensin systemet (RAS), og/ eller har nedsat nyrefunktion og/ eller diabetes mellitus, har en øget risiko for hyperkalæmi under behandling med aliskiren.
Patients receiving other medicinal products inhibiting the renin-angiotensin system (RAS), and/ or those with reduced kidney function and/ or diabetes mellitus are at an increased risk of hyperkalaemia during aliskiren therapy.